Manufacturer narrative: the device history record (dhr) was reviewed, and no abnormalities or concerns were observed.The dhr indicated that the released product met all specifications.Nova biomedical had previously observed an increase in the number of complaints related to heelstick technique when testing blood glucose in neonates.As a result of this, comprehensive testing was performed on multiple strip lots simulating neonate patient usage, and determined that with proper sample collection and handling the system gives accurate results.A preventative action had been previously initiated to revise the labelling to add a precaution in regards to capillary heelstick sample collection.
|